Drugs / MVT-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03882359 | Apr 2019 → Sep 2024 | heart disorder | Microvascular Therapeutics, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVT-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03882359 ↗ |
| Route | Intravenous | “After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.” NCT03882359 ↗ |